Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2011 |
| End Date: | May 2013 |
This study is designed to gather preliminary effectiveness and safety data on the use of
bupropion for smoking cessation in pregnant women attending a community prenatal clinic.
This study will provide critical preliminary data in preparation for a larger, Phase III
clinical trial.
bupropion for smoking cessation in pregnant women attending a community prenatal clinic.
This study will provide critical preliminary data in preparation for a larger, Phase III
clinical trial.
A randomized, double-blind, parallel group design will be used to allow a rigorous
preliminary assessment of the feasibility, effectiveness, and safety of bupropion SR
(sustained release; packaged as Zyban by GlaxoSmithKline) in promoting smoking cessation
among women in their second and third trimester of pregnancy. Fifty pregnant smokers will be
randomized to receive an 8-week course of either bupropion SR or matching placebo tablets.
Both groups will receive evidence-based smoking cessation counseling. The primary smoking
outcome will be 7-day point prevalence abstinence with cotinine validation at the end of the
treatment. Secondary outcomes include enrollment, retention, and compliance rates;
continuous abstinence from end of treatment through the 2 week followup; continuous
abstinence from birth to 2nd week postpartum followup; self-reported reduction in number of
cigarettes smoked per day; and maternal side effects and perinatal/neonatal outcomes.
Preliminary smoking cessation and safety outcomes will be assessed for the generation of
evidence-based hypotheses regarding clinical benefit of bupropion for pregnant smokers in
preparation fo a larger trial.
preliminary assessment of the feasibility, effectiveness, and safety of bupropion SR
(sustained release; packaged as Zyban by GlaxoSmithKline) in promoting smoking cessation
among women in their second and third trimester of pregnancy. Fifty pregnant smokers will be
randomized to receive an 8-week course of either bupropion SR or matching placebo tablets.
Both groups will receive evidence-based smoking cessation counseling. The primary smoking
outcome will be 7-day point prevalence abstinence with cotinine validation at the end of the
treatment. Secondary outcomes include enrollment, retention, and compliance rates;
continuous abstinence from end of treatment through the 2 week followup; continuous
abstinence from birth to 2nd week postpartum followup; self-reported reduction in number of
cigarettes smoked per day; and maternal side effects and perinatal/neonatal outcomes.
Preliminary smoking cessation and safety outcomes will be assessed for the generation of
evidence-based hypotheses regarding clinical benefit of bupropion for pregnant smokers in
preparation fo a larger trial.
Inclusion Criteria:
- Pregnant women ≥ 18 years of age
- Gestational age between 14 and 26 weeks confirmed by ultrasound
- Currently smoking ≥ 5 cigarettes per day
Exclusion Criteria:
- Abnormal liver function tests
- History of or current seizure disorder or closed head injury with loss of
consciousness
- Known hypersensitivity to bupropion
- Any psychiatric disorder requiring psychotropic medication
- Current anorexia or bulimia
- Use of monoamine oxidase (MAO) inhibitors or discontinuation within the past 2 weeks
- Major Depressive Disorder or current suicidal risk
- Use of any illicit substances since receiving knowledge of pregnancy
- Regular use of alcohol (>1 drink/week on average)
- Unstable medical problems, such as liver or renal disease, uncontrollable
hypertension, and lupus
- Twins or other multiple gestation
- Fetal abnormality on the 14 week ultrasound
- Plans to deliver at a hospital other than Memorial Hermann
- Inability to communicate with research staff or make study visits due to lack of
phone or transportation access
- Participation in another clinical study which may affect study outcomes
- Current use of any Nicotine Replacement Therapy (NRT), bupropion, or varenicline
(Chantix)
We found this trial at
1
site
Click here to add this to my saved trials
